Sosei Heptares and Aditum Bio create new company - Tempero Bio - to advance the clinical development of mGlu5 NAM program in neurological diseases

Author's Avatar
Nov 02, 2020
Article's Main Image

- Aditum Bio, established by industry veterans Joe Jimenez and Mark Fishman, to fund clinical development

- Sosei Heptares to receive an upfront payment and strategic equity stake in Tempero Bio, plus future success-based milestone payments and tiered royalties

PR Newswire